The estimated Net Worth of Shannon Thyme Klinger is at least $1.49 Million dollars as of 6 September 2024. Ms Klinger owns over 1,139 units of Moderna Inc stock worth over $1,487,235 and over the last 3 years she sold MRNA stock worth over $0.
Ms has made over 22 trades of the Moderna Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 1,139 units of MRNA stock worth $90,562 on 6 September 2024.
The largest trade she's ever made was exercising 10,247 units of Moderna Inc stock on 7 June 2024 worth over $814,739. On average, Ms trades about 1,241 units every 30 days since 2021. As of 6 September 2024 she still owns at least 18,705 units of Moderna Inc stock.
You can see the complete history of Ms Klinger stock trades at the bottom of the page.
Shannon Thyme Klinger is the Chief Legal Officer & Corp. Sec. at Moderna Inc.
Ms Klinger is 50, she's been the Chief Legal Officer & Corp. Sec. of Moderna Inc since . There are 11 older and 6 younger executives at Moderna Inc. The oldest executive at Moderna Inc is Elizabeth Tallett, 71, who is the Director.
Shannon's mailing address filed with the SEC is 325 BINNEY STREET, , CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, and Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: